4 trending stocks: Poolbeg Pharma, Abingdon Health, BATM, Omega Diagnostics

Follow us on Google News:
 4 trending stocks: Poolbeg Pharma, Abingdon Health, BATM, Omega Diagnostics
Image source: Phongphan, Shutterstock.com

Highlights 

  • Poolbeg Pharma Plc, which recently got listed on the AIM market, is well-positioned to capture business opportunities to participate in the underpenetrated clinical trial market segment.
  • Abingdon Health Plc has announced a new antibody self-test kit that will provide results in 20 minutes.

The flash data for UK’s manufacturing PMI, which accounts for about 10% of British economic output, will be announced later in the day. The actual PMI data from IHS-Markit/CIPS dropped to 60.4 in July 2021 compared to the 63.9 figure reported in June month. The index touched an all-time high of 65.6 in May 2021, supported by the re-opening of the economy and more robust demand in the domestic market after lifting lockdown restrictions.

Let us look at 4 FTSE listed stocks that are trending today:

Poolbeg Pharma Plc (LON: POLB)

UK-based pharma company engages in the clinical stage for infectious diseases. It focuses on developing multiple products with cost-efficient techniques.

The company got listed on the AIM market on 19 July 2021 after being spun out from Open Orphan Plc. The company raised £25 million in its initial public offer (IPO). The funds will be used to acquire and develop infectious disease assets and to fund clinical trial costs.

The company has a broad asset portfolio that provides effective treatment for multiple diseases. The market size of infectious diseases is expected to be over USD 250 billion by 2025. The company is well-positioned to capture business opportunities to participate in the underpenetrated clinical trial market segment. 

Poolbeg Pharma Plc currently trades at GBX 10.50, up by 20.00% on 23 August 2021 at 9.20 am GMT+1 with a market cap of £43.75 million.

Abingdon Health Plc (LON: ABDX)

The company is a leading manufacturer of high-quality rapid test kits. It does contract manufacturing for other companies and also develops its own labelled tests kits.

The company introduced BioSURE COVID-19 IgG Antibody Self-Test. The test will allow the individuals to monitor the antibody status pre-vaccination and post-vaccination by using the fraction of blood drop and giving results in 20 minutes.

Abingdon Health Plc trades at GBX 38.50, up by 26.23% on 23 August 2021 at 9:22 am GMT+1 with a market cap of £29.19 million.

Related Read: Is it the right time to invest in these 5 FTSE listed cannabis stocks?

BATM Advanced Communications LD (LON: BVC)

The company provides real-time technology for networking solutions and bio-medical systems.

The company reported USD 71.4 million in revenue and gross profits of USD 25.7 million in the six months ended 30 June 2021. The bio-medical division contributed 77.1% of the total revenue driven by the sales of Covid-19 diagnostic kits, while the Networking and Cyber division contributed 22.9% of the revenue.

BATM Advanced Communications trades at GBX 90.00, up by 2.51% on 23 August 2021 at 9:23 am GMT+1 with a market cap of £386.70 million.

Omega Diagnostics Group Plc (LON: ODX)

The company manufacture and distributes medical diagnostics products. It focuses on CD4, infectious diseases and food sensitivity testing and its products are used in over 75 countries by hospitals and laboratories.

During the year ended 31 March 2021, the company’s revenue declined by 11% at £8.73 million with an EBITDA loss of £2.20 million. The revenue was down mainly due to Covid-19 impact on the health and nutrition business segment. However, the company expects a recovery in the health and nutrition business with ease in lockdown restrictions globally. 

Omega Diagnostics Group Plc currently trades at GBX 41.00, down by 2.38% on 23 August 2021 at 9:24 am GMT+1 with a market cap of £76.71 million.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.